Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Paice et al v. Aldeyra Therapeutics, Inc. et al
Case Number:
1:23-cv-11737
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
-
March 14, 2025
Biotech Wins Dismissal Of Investor Fraud Claims
A Boston federal judge on Friday dismissed a proposed investor class action against biotech Aldeyra Therapeutics Inc., ruling that the lawsuit's facts tend to support innocent explanations for executives' statements about its two drug prospects.
-
July 31, 2023
Mass. Biotech Co. Hit With Stock Drop Suit Over New Drug
Massachusetts-based biotechnology company Aldeyra Therapeutics Inc. was hit with a proposed class action Monday by investors who claim the company and its top executives made false and misleading statements about a cancer treatment in development, causing damage to investors when the drug's revealed ineffectiveness tanked Aldeyra's stock price.